TBPH
Income statement / Annual
Last year (2024), Theravance Biopharma, Inc.'s total revenue was $64.38 M,
an increase of 12.12% from the previous year.
In 2024, Theravance Biopharma, Inc.'s net income was -$56.42 M.
See Theravance Biopharma, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$64.38 M |
$57.42 M |
$51.35 M |
$55.31 M |
$71.86 M |
$73.41 M |
$60.37 M |
$15.39 M |
$48.65 M |
$42.13 M |
| Cost of Revenue |
$0.00
|
$40.62 M
|
$6.59 M
|
$7.29 M
|
$260.95 M
|
$219.25 M
|
$715,000.00
|
$6.03 M
|
$2.89 M
|
$4.66 M
|
| Gross Profit |
$64.38 M
|
$16.80 M
|
$44.76 M
|
$48.03 M
|
-$189.10 M
|
-$145.83 M
|
$59.66 M
|
$9.36 M
|
$45.75 M
|
$37.47 M
|
| Gross Profit Ratio |
1
|
0.29
|
0.87
|
0.87
|
-2.63
|
-1.99
|
0.99
|
0.61
|
0.94
|
0.89
|
| Research and Development Expenses |
$37.64 M
|
$40.62 M
|
$63.39 M
|
$193.66 M
|
$260.95 M
|
$219.25 M
|
$201.35 M
|
$173.89 M
|
$141.71 M
|
$129.17 M
|
| General & Administrative Expenses |
$0.00
|
$65.00 M
|
$59.07 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$5.10 M
|
$8.00 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$69.17 M
|
$70.10 M
|
$67.07 M
|
$99.30 M
|
$108.66 M
|
$106.08 M
|
$97.06 M
|
$95.59 M
|
$84.51 M
|
$90.20 M
|
| Other Expenses |
$4.51 M
|
$0.00
|
$0.00
|
$0.00
|
-$1.61 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$111.33 M
|
$113.46 M
|
$130.47 M
|
$292.95 M
|
$369.61 M
|
$325.33 M
|
$298.41 M
|
$269.48 M
|
$226.22 M
|
$219.37 M
|
| Cost And Expenses |
$111.33 M
|
$113.46 M
|
$130.47 M
|
$292.95 M
|
$369.61 M
|
$325.33 M
|
$299.12 M
|
$275.51 M
|
$229.12 M
|
$224.03 M
|
| Interest Income |
$4.88 M
|
$9.12 M
|
$8.55 M
|
$1.11 M
|
$2.83 M
|
$8.40 M
|
$11.97 M
|
$4.96 M
|
$1.31 M
|
$631,000.00
|
| Interest Expense |
$2.55 M
|
$2.35 M
|
$6.37 M
|
$46.89 M
|
$44.59 M
|
$31.86 M
|
$10.48 M
|
$8.55 M
|
$1.40 M
|
$0.00
|
| Depreciation & Amortization |
$0.00
|
$6.05 M
|
$6.59 M
|
$7.29 M
|
$6.64 M
|
$6.52 M
|
$3.17 M
|
$4.03 M
|
$3.12 M
|
$2.99 M
|
| EBITDA |
-$46.95 M |
-$40.87 M |
-$79.86 M |
-$249.39 M |
-$294.00 M |
-$203.29 M |
-$212.44 M |
-$259.14 M |
-$176.04 M |
-$178.77 M |
| EBITDA Ratio |
-0.73
|
-0.71
|
-1.37
|
-2.4
|
-3.15
|
-2.86
|
-3.57
|
-16.58
|
-3.68
|
-4.25
|
| Operating Income Ratio |
-0.73
|
-0.98
|
-1.79
|
-4.66
|
-4.14
|
-3.43
|
-3.95
|
-16.91
|
-3.71
|
-4.32
|
| Total Other Income/Expenses Net |
$2.34 M
|
$6.77 M
|
-$858,000.00
|
-$7.44 M
|
$11.22 M
|
$10.24 M
|
$12.67 M
|
-$11.59 M
|
-$92,000.00
|
$631,000.00
|
| Income Before Tax |
-$44.61 M
|
-$49.27 M
|
-$92.82 M
|
-$199.58 M
|
-$286.54 M
|
-$241.68 M
|
-$226.09 M
|
-$271.71 M
|
-$180.56 M
|
-$181.27 M
|
| Income Before Tax Ratio |
-0.69
|
-0.86
|
-1.81
|
-3.61
|
-3.99
|
-3.29
|
-3.74
|
-17.66
|
-3.71
|
-4.3
|
| Income Tax Expense |
$11.80 M
|
$5.92 M
|
$9,000.00
|
-$151,000.00
|
-$8.52 M
|
-$5.22 M
|
-$10.56 M
|
$13.69 M
|
$10.11 M
|
$951,000.00
|
| Net Income |
-$56.42 M
|
-$55.19 M
|
-$92.82 M
|
-$199.43 M
|
-$278.02 M
|
-$236.46 M
|
-$215.52 M
|
-$285.41 M
|
-$190.67 M
|
-$182.22 M
|
| Net Income Ratio |
-0.88
|
-0.96
|
-1.81
|
-3.61
|
-3.87
|
-3.22
|
-3.57
|
-18.55
|
-3.92
|
-4.33
|
| EPS |
-1.15 |
-1 |
-1.26 |
-2.87 |
-4.46 |
-4.25 |
-3.99 |
-5.45 |
-4.26 |
-5.34 |
| EPS Diluted |
-1.15 |
-1 |
-1.26 |
-2.87 |
-4.46 |
-4.25 |
-3.99 |
-5.45 |
-4.26 |
-5.34 |
| Weighted Average Shares Out |
$48.85 M
|
$55.30 M
|
$73.59 M
|
$69.46 M
|
$62.35 M
|
$55.61 M
|
$53.97 M
|
$52.35 M
|
$44.71 M
|
$34.15 M
|
| Weighted Average Shares Out Diluted |
$48.85 M
|
$55.30 M
|
$73.59 M
|
$69.46 M
|
$62.35 M
|
$55.61 M
|
$53.97 M
|
$52.35 M
|
$44.71 M
|
$34.15 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
